Equillium, Inc. (EQ)

NCM – Real vaqt narxi. Valyuta: USD

2.27

+0.02 (0.89%)

Yopilishda: May 12, 2026, 4:00 PM EDT

01.05.2026

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LA JOLLA, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on May 1, 2026, the Compensation Committee of Equillium's Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase an aggregate of 800,000 shares of common stock to two new employees under Equillium's 2024 Inducement Plan. The Compensation Committee approved the stock option grants as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).

28.04.2026

Equiniti (EQ) Launches DealTrax™: A Digital-First Platform for Corporate Actions and M&A Events

DealTrax Highlights Include: Powerful Tools & Streamlined Processes: Quick, efficient deal setup with digital capabilities Speed: Faster payment delivery to holders Seamless Delivery: Full-service support including Escrow Agent services Scalability: Built to support today's workflows and tomorrow's events NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Equiniti (EQ), a leading FinTech firm that connects the future of capital, communication and governance, announced the launch of DealTrax, its next-generation online portal designed to transform how organizations manage complex corporate actions and private M&A transactions. Built for today's fast-paced markets, DealTrax delivers a modern, digital-first experience that replaces manual processes and physical mail with automated, straight-through execution.

20.04.2026

Equillium to Participate in Oppenheimer's 2026 Innovation on the Island Event

LA JOLLA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will be presenting at Oppenheimer's 2026 Innovation on the Island Event on Tuesday April 28, 2026 at 7:50am AST.

08.04.2026

Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists

LA JOLLA, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new EQ504 preclinical data have been accepted for poster presentations at IMMUNOLOGY2026™, the annual meeting of the American Association of Immunologists taking place in Boston, Massachusetts, April 15-19, 2026.

02.04.2026

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LA JOLLA, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on April 1, 2026, the Compensation Committee of Equillium's Board of Directors granted an inducement award consisting of nonstatutory stock options to purchase a total of 32,000 shares of common stock to a new employee under Equillium's 2024 Inducement Plan. The Compensation Committee approved the stock option as an inducement material to such employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4).

25.03.2026

Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights

Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafter

18.03.2026

Equillium to Participate in the 38th Annual Roth Conference

LA JOLLA, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 38th Annual Roth Conference for Growth Companies on Monday, March 23, 2026 at 8:30am PT.

Videolar

No Data

There is no data to display

Press-relizlar

01.05.2026

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

28.04.2026

Equiniti (EQ) Launches DealTrax™: A Digital-First Platform for Corporate Actions and M&A Events

20.04.2026

Equillium to Participate in Oppenheimer's 2026 Innovation on the Island Event

08.04.2026

Equillium, Inc. (EQ)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Equillium, Inc. (EQ)

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Equiniti (EQ) Launches DealTrax™: A Digital-First Platform for Corporate Actions and M&A Events

Equillium to Participate in Oppenheimer's 2026 Innovation on the Island Event

Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights

Equillium to Participate in the 38th Annual Roth Conference

Videolar

No Data

Press-relizlar

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Equiniti (EQ) Launches DealTrax™: A Digital-First Platform for Corporate Actions and M&A Events

Equillium to Participate in Oppenheimer's 2026 Innovation on the Island Event

Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Equiniti (EQ) Launches DealTrax™: A Digital-First Platform for Corporate Actions and M&A Events

Equillium to Participate in Oppenheimer's 2026 Innovation on the Island Event

Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights

Equillium to Participate in the 38th Annual Roth Conference

Videolar

No Data

Press-relizlar

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Equiniti (EQ) Launches DealTrax™: A Digital-First Platform for Corporate Actions and M&A Events

Equillium to Participate in Oppenheimer's 2026 Innovation on the Island Event

Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists

Search stocks

Equillium, Inc. (EQ)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Equillium, Inc. (EQ)

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Equiniti (EQ) Launches DealTrax™: A Digital-First Platform for Corporate Actions and M&A Events

Equillium to Participate in Oppenheimer's 2026 Innovation on the Island Event

Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights

Equillium to Participate in the 38th Annual Roth Conference

Videolar

No Data

Press-relizlar

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Equiniti (EQ) Launches DealTrax™: A Digital-First Platform for Corporate Actions and M&A Events

Equillium to Participate in Oppenheimer's 2026 Innovation on the Island Event

Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Equiniti (EQ) Launches DealTrax™: A Digital-First Platform for Corporate Actions and M&A Events

Equillium to Participate in Oppenheimer's 2026 Innovation on the Island Event

Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights

Equillium to Participate in the 38th Annual Roth Conference

Videolar

No Data

Press-relizlar

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Equiniti (EQ) Launches DealTrax™: A Digital-First Platform for Corporate Actions and M&A Events

Equillium to Participate in Oppenheimer's 2026 Innovation on the Island Event

Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists